Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000031

Drug Information
NameBuspirone
SynonymsNCGC00024905-01; AC1L1DRN; Bespar; SPBio_002418; BRD-K93461745-003-03-7; HMS2090K19; LS-22723; Ansiced; KBio2_002236; IDI1_000921; CHEMBL49; 8-Azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)-; CHEBI:3223; Gen-Buspirone (TN); C13H21NO2.C9H14N4; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; AKOS002313325; Tocris-0962; KBio2_007372; Buspirone (INN); KBioSS_002236; KBio1_000921; CAS-33386-08-2; CID2477; Biomol-NT_000108; Prestwick1_000369; STOCK1S-11244; Prestwick0_000369; Axoren; Anxiron; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-; 8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; Buspirone-MDTS; MolPort-002-539-709; MJ-9022-1; AB00053432; Buspisal; Gen-Buspirone; C06861; EINECS 253-072-2; NCGC00015162-01; Buspironum [INN-Latin]; KBio2_004804; BSPBio_000497; Lopac0_000223; UNII-TK65WKS8HL; Buspirona; D07593; DB00490; BAS 00928841; NINDS_000921; BPBio1_000547; Buspironum; 36505-84-7; BPBio1_001403; NCGC00024905-03; NCGC00015162-06; Buspirone [INN:BAN]; STK086268; L001110; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; Spectrum_001756; NCGC00016820-01; BRN 0964904; buspirone; DivK1c_000921; Buspirona [INN-Spanish]; Prestwick3_000369; Prestwick2_000369; Ansial; BIDD:GT0519; BRD-K93461745-001-01-5; Lopac-B-7148; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; NCGC00024905-02; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
Trade NameBuSpar; Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspimen; Buspinol; Buspiron; Buspisal; Narol; Spamilan; Spitomin; Sorbon
CompanyBristol-Myers Squibb
IndicationAnxiety disorder
[ICD9: 300   ICD10: F40-F42]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24
-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
InChIKeyQWCRAEMEVRGPNT-UHFFFAOYSA-N
Canonical SMILESC1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4    
Therapeutic ClassAnti-anxiety Agents
CAS NumberCAS 36505-84-7
FormulaC21H31N5O2
PubChem Compound IDCID 2477.
PubChem Substance IDSID 9079.
ChEBI3223;
SuperDrug ATC IDN05BE01
SuperDrug CAS ID036505847;
Target5-hydroxytryptamine 1A receptorAgonist[2]
Ref 1Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug;9(4):278-83. To Reference
Ref 2Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543